InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

- Current share price for SPL : $0.725

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$346 Notice of Annual General Meeting/Proxy Form 28 Oct 2022 2:23PM $0.538 $0.725 risen by 34.88%
$346 Application for quotation of securities - SPL 27 Oct 2022 2:42PM $0.550 $0.725 risen by 31.82%
$346 Notification regarding unquoted securities - SPL 27 Oct 2022 2:40PM $0.550 $0.725 risen by 31.82%
$346 Quarterly Activities Report & Appendix 4C 26 Oct 2022 9:57AM $0.570 $0.725 risen by 27.19%
$346 VIRALEZE distribution agreement for Hong Kong and Macau 21 Oct 2022 9:42AM $0.600 $0.725 risen by 20.83%
$346 Change in substantial holding 21 Oct 2022 8:18AM $0.600 $0.725 risen by 20.83%
$346 Change in Director's Interest Notice - J Fairley 7 Oct 2022 1:17PM $0.670 $0.725 risen by 8.21%
$346 Notification of cessation of securities - SPL 7 Oct 2022 1:12PM $0.670 $0.725 risen by 8.21%
$346 Board Renewal 5 Oct 2022 1:18PM $0.588 $0.725 risen by 23.40%
$346 2022 Annual General Meeting Date 30 Sep 2022 2:28PM $0.605 $0.725 risen by 19.83%
$346 Starpharma to present at Life Sciences Investor Forum 15 Sep 2022 4:24PM $0.580 $0.725 risen by 25%
$346 Change in substantial holding 12 Sep 2022 4:38PM $0.580 $0.725 risen by 25%
$346 Change in Director's Interest Notice - J Fairley 12 Sep 2022 2:08PM $0.575 $0.725 risen by 26.09%
$346 New clinical data for DEP cabazitaxel in prostate cancer 12 Sep 2022 9:20AM $0.585 $0.725 risen by 23.93%
$346 S&P DJI Announces September 2022 Quarterly Rebalance 2 Sep 2022 5:01PM $0.630 $0.725 risen by 15.08%
$346 Starpharma annual report and full year financial results 25 Aug 2022 9:42AM $0.710 $0.725 risen by 2.11%
$346 Appendix 4G - Corporate Governance Statement 25 Aug 2022 9:42AM $0.710 $0.725 risen by 2.11%
$346 Starpharma signs new DEP agreement with MSD 10 Aug 2022 9:59AM $0.740 $0.725 fallen by 2.03%
$346 Quarterly Activities Report & Appendix 4C 29 Jul 2022 9:39AM $0.650 $0.725 risen by 11.54%
$346 VIRALEZE Protects Against Omicron in Viral Challenge Model 20 Jul 2022 10:35AM $0.665 $0.725 risen by 9.02%
$346 Change in substantial holding 5 Jul 2022 6:25PM $0.695 $0.725 risen by 4.32%
$346 VIRALEZE relaunched by LloydsPharmacy in the UK 30 Jun 2022 9:47AM $0.670 $0.725 risen by 8.21%
$346 SPL signs expanded DEP research agreement with US Biopharma 27 Jun 2022 9:19AM $0.720 $0.725 risen by 0.69%
$346 Shareholder Newsletter 3 Jun 2022 1:22PM $0.728 $0.725 fallen by 0.34%
$346 Notification of cessation of securities - SPL 27 May 2022 1:55PM $0.748 $0.725 fallen by 3.01%

226 - 250 of 875 results

Page 10 of 35

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.